Results of multivariate Cox regression analysis on factors associated with CNS relapse in the COO-available population (n = 933)
| Factor . | HR* . | 95% CI . | P . |
|---|---|---|---|
| CNS-IPI intermediate (vs low) | 0.88 | 0.29-2.74 | .8312 |
| CNS-IPI high (vs low) | 3.97 | 1.28-12.33 | .0172 |
| ABC COO (vs GCB) | 5.18 | 2.09-12.87 | .0004 |
| Unclassified COO (vs GCB) | 4.18 | 1.50-11.66 | .0062 |
| Factor . | HR* . | 95% CI . | P . |
|---|---|---|---|
| CNS-IPI intermediate (vs low) | 0.88 | 0.29-2.74 | .8312 |
| CNS-IPI high (vs low) | 3.97 | 1.28-12.33 | .0172 |
| ABC COO (vs GCB) | 5.18 | 2.09-12.87 | .0004 |
| Unclassified COO (vs GCB) | 4.18 | 1.50-11.66 | .0062 |
CNS relapses, n = 30. Factors that were significantly associated with greater CNS relapse risk are highlighted in bold.
Adjusted for study randomization stratification factors (number of planned chemotherapy cycles, geographic region).